The collaboration opens up opportunities for co-development of advanced assets to be deployed in Spain and India, said Immuneel in a press release. Immuneel acquired the exclusive rights to develop and commercialise autologous ARI-0001 – a CD19 Chimeric antigen receptor (CAR) T cell therapy, in India.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/36WQJ65
via IFTTT
0 comments:
Post a Comment